fda safety communication semaglutide naion 2025 Ozempic Lawsuit for Blindness, Stomach Paralysis and Injury Claims

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for diabetes that belong to

23.83

★★★★☆4.8 (126)

Ozempic Blindness Lawsuit [2026 Guide]

20.04

★★★★★4.9 (98)

A large FDA adverse event analysis shows that #semaglutide, especially the higher-dose weight-loss formulation Wegovy, is strongly associated with #ischemic #optic #neuropathy, with a significantly higher risk in men, suggesting a potential

25.85

★★★★★5.0 (157)

The FDA has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and

26.17

★★★★★4.7 (84)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

23.38

★★★★★4.9 (203)

The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added

29.83

★★★★★5.0 (176)

March 31, 2025: Senator asks how FDA will be accountable for unregulated active pharmaceutical ingredient (API) imports – Partnership for Safe Medicines

20.28

★★★★★4.8 (132)